Vemurafenib, a second-generation selective small molecule inhibitor of RAF, is highly potent in inhibiting the activation of this pathway in BRAF V600E-mutant melanoma cells and thereby is highly effective in combating the growth of metastases in the melanoma patients (for review, see 2). This evidence concerns the gene BRAF and melanoma.